AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2873173 — intervention group
Group type: COMPARATOR
Intervention: Cephazolin iv at induction of anaesthesia
Number of subjects: 100
Study 29565716 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein isolates (40g) plus zinc and selenium
Number of subjects: 42
Study 29565716 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin oral snack
Number of subjects: 42
Study 27809945 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey Protein Isolate (WPI)
Number of subjects: 20
Study 27809945 — intervention group
Group type: COMPARATOR
Intervention: Free Amino Acid Mixture (AAM)
Number of subjects: 20
Study 24234041 — intervention group
Group type: EXPERIMENTAL
Intervention: Pigeons
Number of subjects: 0
Study 24234041 — intervention group
Group type: EXPERIMENTAL
Intervention: Humans
Number of subjects: 0
Study 22092692 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium lactis
Number of subjects: 208
Study 22092692 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei
Number of subjects: 208
Study 22092692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study 22092692 — intervention group
Group type: COMPARATOR
Intervention: Observational group (exclusively breastfed)
Number of subjects: 208
Study 22092692 — intervention group
Group type: COMPARATOR
Intervention: Observational group (standard formula-fed)
Number of subjects: 208
Study 15965213 — intervention group
Group type: EXPERIMENTAL
Intervention: Family support
Number of subjects: 0
Study 15965213 — intervention group
Group type: COMPARATOR
Intervention: Normal care
Number of subjects: 0
Study 12143909 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy with Melissa essential oil (N = 36)
Number of subjects: 72
Study 12143909 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sunflower oil) (N = 36)
Number of subjects: 72
Study 12143909 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy with Melissa essential oil
Number of subjects: 72
Study 9933749 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin 10 mg/day for 3 months
Number of subjects: 20
Study 9933749 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 20
Study 7501717 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation with analgesia
Number of subjects: 0
Study 7501717 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation without analgesia
Number of subjects: 0
Study 7501717 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled medication delivery
Number of subjects: 0
Study 2305603 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg/day ciamexone
Number of subjects: 51
Study 2305603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 6252466 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptozocin plus fluorouracil
Number of subjects: 84
Study 30081719 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel fluoride‐containing bioactive glass (QMAT3)
Number of subjects: 30
Study 30081719 — intervention group
Group type: COMPARATOR
Intervention: Sylc glass
Number of subjects: 30
Study 30081719 — intervention group
Group type: COMPARATOR
Intervention: Artificial saliva
Number of subjects: 30
Study 28766537 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy with bortezomib for 1 year
Number of subjects: 52
Study 28766537 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy with bortezomib
Number of subjects: 52
Study 28766537 — intervention group
Group type: COMPARATOR
Intervention: No maintenance therapy (control group)
Number of subjects: 52
Study 25568415 — intervention group
Group type: COMPARATOR
Intervention: Kinemax TKA (group 1)
Number of subjects: 212
Study 25568415 — intervention group
Group type: EXPERIMENTAL
Intervention: Triathlon TKA (group 2)
Number of subjects: 212
Study 23696793 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler-guided prospective ECG gating
Number of subjects: 119
Study 23696793 — intervention group
Group type: COMPARATOR
Intervention: Traditional prospective ECG gating
Number of subjects: 119
Study 21685549 — intervention group
Group type: EXPERIMENTAL
Intervention: stavudine/lamivudine (d4T/3TC)
Number of subjects: 1771
Study 21685549 — intervention group
Group type: EXPERIMENTAL
Intervention: didanosine/zidovudine
Number of subjects: 1771
Study 19085578 — intervention group
Group type: COMPARATOR
Intervention: Indacaterol 100 micro g
Number of subjects: 115
Study 19085578 — intervention group
Group type: COMPARATOR
Intervention: Indacaterol 200 micro g
Number of subjects: 115
Study 19085578 — intervention group
Group type: COMPARATOR
Intervention: Indacaterol 300 micro g
Number of subjects: 115
Study 19085578 — intervention group
Group type: COMPARATOR
Intervention: Indacaterol 400 micro g
Number of subjects: 115
Study 19085578 — intervention group
Group type: COMPARATOR
Intervention: Indacaterol 600 micro g
Number of subjects: 115
Study 19085578 — intervention group
Group type: COMPARATOR
Intervention: Formoterol 12 micro g twice daily (open-label after washout)
Number of subjects: 115
Study 16925855 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 2724
Study 16925855 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary activities
Number of subjects: 2724
Study 12953180 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (50mg zinc gluconate)
Number of subjects: 14
Study 12953180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 11245556 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based clinical guidelines
Number of subjects: 0
Study 11245556 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochrane systematic reviews
Number of subjects: 0
Study 9089849 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 mg)
Number of subjects: 20
Study 9089849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1590686 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid infusion of amphotericin B (45 min)
Number of subjects: 20
Study 1590686 — intervention group
Group type: COMPARATOR
Intervention: Slow infusion of amphotericin B (4 h)
Number of subjects: 20
Study 1590686 — intervention group
Group type: EXPERIMENTAL
Intervention: Both infusion rates
Number of subjects: 20
Study 3703098 — intervention group
Group type: COMPARATOR
Intervention: 0% blood alcohol (control)
Number of subjects: 21
Study 3703098 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% blood alcohol (ethanol intervention)
Number of subjects: 21
Study 30232048 — intervention group
Group type: EXPERIMENTAL
Intervention: BGF MDI (budesonide/glycopyrrolate/formoterol fumarate metered‐dose inhaler 320/18/9·6 μg)
Number of subjects: 1902
Study 30232048 — intervention group
Group type: EXPERIMENTAL
Intervention: BGF MDI
Number of subjects: 1902
Study 30232048 — intervention group
Group type: COMPARATOR
Intervention: GFF MDI (glycopyrrolate/formoterol fumarate metered‐dose inhaler 18/9·6 μg)
Number of subjects: 1902
Study 30232048 — intervention group
Group type: COMPARATOR
Intervention: BFF MDI (budesonide/formoterol fumarate metered‐dose inhaler 320/9·6 μg)
Number of subjects: 1902
Study 30232048 — intervention group
Group type: COMPARATOR
Intervention: BUD/FORM DPI (budesonide/formoterol fumarate dry‐powder inhaler 400/12 μg)
Number of subjects: 1902
Study 27111751 — intervention group
Group type: EXPERIMENTAL
Intervention: STEPS‐UP (stepped, centrally assisted collaborative care model)
Number of subjects: 666
Study 27111751 — intervention group
Group type: COMPARATOR
Intervention: Usual collaborative care (control)
Number of subjects: 666
Study 25487708 — intervention group
Group type: EXPERIMENTAL
Intervention: SIRT + mFOLFOX6 (with a reduced dose of oxaliplatin in cycles 1-3 following SIRT)
Number of subjects: 450
Study 25487708 — intervention group
Group type: COMPARATOR
Intervention: mFOLFOX6
Number of subjects: 450
Study 23265037 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg orally one hour before surgery
Number of subjects: 44
Study 23265037 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 44
Study 20658007 — intervention group
Group type: EXPERIMENTAL
Intervention: Epley maneuver associated with the use of neck collar and post‐maneuver instructions
Number of subjects: 53
Study 20658007 — intervention group
Group type: EXPERIMENTAL
Intervention: Epley maneuver without the use of cervical collar and/or post‐maneuver restrictions
Number of subjects: 53
Study 20658007 — intervention group
Group type: EXPERIMENTAL
Intervention: Epley maneuver associated with the use of a mini vibrator, without the use of neck collar and/or post‐maneuver restrictions
Number of subjects: 53
Study 18503906 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase (2 mg or 4 mg based on infusion volumes of 0-50 mL or 51-100 mL, administered twice daily for 3 days)
Number of subjects: 20
Study 18503906 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (administered twice daily for 3 days)
Number of subjects: 20
Study 15922697 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg once nightly)
Number of subjects: 400
Study 15922697 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone (88 mug twice daily)
Number of subjects: 400
Study 15922697 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone and Montelukast
Number of subjects: 400
Study 15922697 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone
Number of subjects: 400
Study 12782903 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined-strength and aerobic exercise program (2 strength sessions at 60% of 1 repetition maximum and 2 aerobic sessions at 60%-85% of maximum heart rate) for 8 months
Number of subjects: 27
Study 12782903 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined-strength and aerobic exercise program (2 strength sessions at 60% of 1 repetition maximum and 2 aerobic sessions at 60%-85% of maximum heart rate) for 8 months followed by 3 months of detraining
Number of subjects: 27
Study 12782903 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 27
Study 10227569 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondiabetic siblings who perceived themselves at increased risk of diabetes
Number of subjects: 540
Study 10227569 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondiabetic siblings who thought diabetes was a serious problem
Number of subjects: 540
Study 10227569 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors predicting perceptions of diabetes risk
Number of subjects: 540
Study 10227569 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors predicting increased likelihood perception
Number of subjects: 540
Study 10227569 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of vulnerability to diabetes
Number of subjects: 540
Study 8546909 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms kg‐1 intravenously (i.v.) on day 1, dexamethasone 20 mg i.v. on days 2 and 3 and prochlorperazine 5 mg orally thrice daily on days 1‐5
Number of subjects: 70
Study 8546909 — intervention group
Group type: COMPARATOR
Intervention: Granisetron 40 micrograms kg‐1 i.v. on day 1 alone
Number of subjects: 70
Study 1890517 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal ketamine (5 mg/kg)
Number of subjects: 60
Study 1890517 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal midazolam (0.30 mg/kg)
Number of subjects: 60
Study 1890517 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous midazolam (0.05 mg/kg) after induction
Number of subjects: 60
Study 1890517 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 60
Study 1890517 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 60
Study 6120350 — intervention group
Group type: EXPERIMENTAL
Intervention: Etretinate ('Tigason')
Number of subjects: 50
Study 6120350 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 31661431 — intervention group
Group type: EXPERIMENTAL
Intervention: DELTA2 recommendations for choosing the target difference in sample size calculations
Number of subjects: 0
Study 31661431 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 28964591 — intervention group
Group type: EXPERIMENTAL
Intervention: Trofinetide 35 mg/kg twice daily for 14 days
Number of subjects: 56
Study 28964591 — intervention group
Group type: EXPERIMENTAL
Intervention: Trofinetide 35 mg/kg twice daily for 28 days
Number of subjects: 56
Study 28964591 — intervention group
Group type: EXPERIMENTAL
Intervention: Trofinetide 70 mg/kg twice daily for 28 days
Number of subjects: 56
Study 28964591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 25562205 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine 3-6 mg/d
Number of subjects: 497
Study 25562205 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine 6-12 mg/d
Number of subjects: 497
Study 25562205 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 497
Study 24227821 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized prophylaxis (25‐65 IU/kg every 3‐5 days, n = 118)
Number of subjects: 165
Study 24227821 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly prophylaxis (65 IU/kg, n = 24)
Number of subjects: 165
Study 24227821 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodic treatment (10‐50 IU/kg, n = 23)
Number of subjects: 165
Study 24227821 — intervention group
Group type: COMPARATOR
Intervention: rFVIIIFc
Number of subjects: 165
Study 23142049 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective anteromedial (AM) bundle reconstruction
Number of subjects: 54
Study 23142049 — intervention group
Group type: COMPARATOR
Intervention: Standard anatomic single-bundle reconstruction
Number of subjects: 54
Study 19403640 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous fumarate
Number of subjects: 235
Study 19403640 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric pyrophosphate
Number of subjects: 235
Study 19403640 — intervention group
Group type: COMPARATOR
Intervention: Ferrous sulfate
Number of subjects: 235
Study 18163065 — intervention group
Group type: EXPERIMENTAL
Intervention: Moving pulse magnetic field (MPMF) treatment
Number of subjects: 145
Study 18163065 — intervention group
Group type: COMPARATOR
Intervention: Traditional physical methods
Number of subjects: 145
Study 15132444 — intervention group
Group type: EXPERIMENTAL
Intervention: Fan-type rapid maxillary expansion (RME)
Number of subjects: 34
Study 15132444 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion (RME)
Number of subjects: 34
Study 15132444 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study 11817775 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin (150 mg/day)
Number of subjects: 47
Study 11817775 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain aspirin (150 mg/day)
Number of subjects: 47
Study 11817775 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aspirin)
Number of subjects: 47
Study 9536226 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriene ointment 0.005%
Number of subjects: 30
Study 9536226 — intervention group
Group type: COMPARATOR
Intervention: Vehicle treatment
Number of subjects: 30
Study 7662599 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-delivery diltiazem 180 mg qd
Number of subjects: 0
Study 7662599 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-delivery diltiazem 360 mg qd
Number of subjects: 0
Study 7662599 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release diltiazem 60 mg tid
Number of subjects: 0
Study 7662599 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release diltiazem 120 mg tid
Number of subjects: 0
Study 2678881 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytobrush
Number of subjects: 126
Study 2678881 — intervention group
Group type: COMPARATOR
Intervention: ENT-swabs
Number of subjects: 126
Study 2678881 — intervention group
Group type: COMPARATOR
Intervention: White, cotton-tipped swabs
Number of subjects: 126
Study 2678881 — intervention group
Group type: COMPARATOR
Intervention: Pathologic wet smear
Number of subjects: 126
Study 1180955 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prostaglandin E2 tablets 0.5 mg hourly
Number of subjects: 106
Study 1180955 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin
Number of subjects: 106
Study 1180955 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prostaglandin E2 tablets
Number of subjects: 106
Study 31666302 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow method of tenaculum placement (closure over a 5‐s period)
Number of subjects: 66
Study 31666302 — intervention group
Group type: COMPARATOR
Intervention: Cough method of tenaculum placement (closure at the time of patient's cough)
Number of subjects: 66
Study 31666302 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall pain scores
Number of subjects: 66
Study 31666302 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider satisfaction
Number of subjects: 66
Study 30454671 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling plus patches
Number of subjects: 4268696
Study 30454671 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling plus gift card
Number of subjects: 4268696
Study 30454671 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling plus patches and gift card
Number of subjects: 4268696
Study 30454671 — intervention group
Group type: COMPARATOR
Intervention: Counseling only
Number of subjects: 4268696
Study 27321097 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible GnRH antagonist protocol
Number of subjects: 90
Study 27321097 — intervention group
Group type: COMPARATOR
Intervention: Long GnRH agonist protocol
Number of subjects: 90
Study 24571886 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost/timolol fixed combination (0.03% bimatoprost and 0.5% timolol, once daily at 19:00 P.M.)
Number of subjects: 235
Study 24571886 — intervention group
Group type: COMPARATOR
Intervention: Concurrent treatment (0.03% bimatoprost followed by 0.5% timolol, once daily at 19:00 P.M.)
Number of subjects: 235
Study 24571886 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost/timolol fixed combination
Number of subjects: 235
Study 24571886 — intervention group
Group type: COMPARATOR
Intervention: Concurrent treatment
Number of subjects: 235
Study 22429099 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient geriatric consultation teams (IGCTs)
Number of subjects: 171
Study 22429099 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 171
Study 19622117 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir 0.5 mg/day
Number of subjects: 709
Study 19622117 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine 100 mg/day
Number of subjects: 709
Study 18614945 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-glucan (5.6 g x d(‐1))
Number of subjects: 36
Study 18614945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 15728041 — intervention group
Group type: EXPERIMENTAL
Intervention: Deltoid tuberosity landmark
Number of subjects: 60
Study 15728041 — intervention group
Group type: COMPARATOR
Intervention: Standard approach
Number of subjects: 60
Study 11354578 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmyocardial laser revascularization (TMR)
Number of subjects: 100
Study 11354578 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment alone (Control)
Number of subjects: 100
Study 9330152 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-injection transthecal digital block technique
Number of subjects: 20
Study 9330152 — intervention group
Group type: COMPARATOR
Intervention: Single-injection subcutaneous technique
Number of subjects: 20
Study 8198024 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin therapy
Number of subjects: 429
Study 8198024 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine, 8 g/day
Number of subjects: 429
Study 8198024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 429
Study 3295315 — intervention group
Group type: EXPERIMENTAL
Intervention: colestipol-niacin therapy
Number of subjects: 162
Study 2695381 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 120 mg t.i.d.
Number of subjects: 16
Study 2695381 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31064203 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping Long Term with Active Suicide Program (CLASP‐A)
Number of subjects: 50
Study 31064203 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Treatment as Usual (ETAU)
Number of subjects: 50
Study 28214370 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (50 mg)
Number of subjects: 42
Study 28214370 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 mL normal saline)
Number of subjects: 42
Study 26204114 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarterly feedback reporting
Number of subjects: 2167
Study 26204114 — intervention group
Group type: COMPARATOR
Intervention: Control group (no feedback reporting)
Number of subjects: 2167
Study 26204114 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 2167
Study 22517566 — intervention group
Group type: EXPERIMENTAL
Intervention: multivessel percutaneous coronary intervention (mv‐PCI)
Number of subjects: 585
Study 22517566 — intervention group
Group type: COMPARATOR
Intervention: coronary artery bypass graft surgery (CABG)
Number of subjects: 585
Study 21823383 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (0.1 mg/kg for children < 40 kg, 4 mg for children > 40 kg)
Number of subjects: 70
Study 21823383 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline 2 ml)
Number of subjects: 70
Study 21823383 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 70
Study 21823383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 21823383 — intervention group
Group type: EXPERIMENTAL
Intervention: Agitated patients
Number of subjects: 70
Study 19145638 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medicinal herb complex (CCMH; a mixture of citronellol and extracts of G. lucidum, C. pilosula and A. sinensis)
Number of subjects: 105
Study 19145638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 19145638 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medicinal herb complex (CCMH)
Number of subjects: 105